Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T22274
(Former ID: TTDNC00542)
|
|||||
Target Name |
Histone deacetylase 6 (HDAC6)
|
|||||
Synonyms |
KIAA0901; JM21; HD6
Click to Show/Hide
|
|||||
Gene Name |
HDAC6
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Multiple myeloma [ICD-11: 2A83] | |||||
2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
Function |
Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
Click to Show/Hide
|
|||||
BioChemical Class |
Carbon-nitrogen hydrolase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.5.1.98
|
|||||
Sequence |
MTSTGQDSTTTRQRRSRQNPQSPPQDSSVTSKRNIKKGAVPRSIPNLAEVKKKGKMKKLG
QAMEEDLIVGLQGMDLNLEAEALAGTGLVLDEQLNEFHCLWDDSFPEGPERLHAIKEQLI QEGLLDRCVSFQARFAEKEELMLVHSLEYIDLMETTQYMNEGELRVLADTYDSVYLHPNS YSCACLASGSVLRLVDAVLGAEIRNGMAIIRPPGHHAQHSLMDGYCMFNHVAVAARYAQQ KHRIRRVLIVDWDVHHGQGTQFTFDQDPSVLYFSIHRYEQGRFWPHLKASNWSTTGFGQG QGYTINVPWNQVGMRDADYIAAFLHVLLPVALEFQPQLVLVAAGFDALQGDPKGEMAATP AGFAQLTHLLMGLAGGKLILSLEGGYNLRALAEGVSASLHTLLGDPCPMLESPGAPCRSA QASVSCALEALEPFWEVLVRSTETVERDNMEEDNVEESEEEGPWEPPVLPILTWPVLQSR TGLVYDQNMMNHCNLWDSHHPEVPQRILRIMCRLEELGLAGRCLTLTPRPATEAELLTCH SAEYVGHLRATEKMKTRELHRESSNFDSIYICPSTFACAQLATGAACRLVEAVLSGEVLN GAAVVRPPGHHAEQDAACGFCFFNSVAVAARHAQTISGHALRILIVDWDVHHGNGTQHMF EDDPSVLYVSLHRYDHGTFFPMGDEGASSQIGRAAGTGFTVNVAWNGPRMGDADYLAAWH RLVLPIAYEFNPELVLVSAGFDAARGDPLGGCQVSPEGYAHLTHLLMGLASGRIILILEG GYNLTSISESMAACTRSLLGDPPPLLTLPRPPLSGALASITETIQVHRRYWRSLRVMKVE DREGPSSSKLVTKKAPQPAKPRLAERMTTREKKVLEAGMGKVTSASFGEESTPGQTNSET AVVALTQDQPSEAATGGATLAQTISEAAIGGAMLGQTTSEEAVGGATPDQTTSEETVGGA ILDQTTSEDAVGGATLGQTTSEEAVGGATLAQTTSEAAMEGATLDQTTSEEAPGGTELIQ TPLASSTDHQTPPTSPVQGTTPQISPSTLIGSLRTLELGSESQGASESQAPGEENLLGEA AGGQDMADSMLMQGSRGLTDQAIFYAVTPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQ ENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKN IAHQNKFGEDMPHPH Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T77PFO |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | Citarinostat | Drug Info | Phase 1 | Multiple myeloma | [2] | |
2 | KA2507 | Drug Info | Phase 1 | Solid tumour/cancer | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 171 Inhibitor drugs | + | ||||
1 | Citarinostat | Drug Info | [2] | |||
2 | KA2507 | Drug Info | [2] | |||
3 | Diaryl amine derivative 2 | Drug Info | [3] | |||
4 | Diaryl amine derivative 3 | Drug Info | [3] | |||
5 | Diaryl amine derivative 4 | Drug Info | [3] | |||
6 | PMID28092474-Compound-32a | Drug Info | [3] | |||
7 | PMID28092474-Compound-32b | Drug Info | [3] | |||
8 | PMID28092474-Compound-32c | Drug Info | [3] | |||
9 | PMID28092474-Compound-32d | Drug Info | [3] | |||
10 | PMID28092474-Compound-32e | Drug Info | [3] | |||
11 | PMID28092474-Compound-32f | Drug Info | [3] | |||
12 | PMID28092474-Compound-32g | Drug Info | [3] | |||
13 | PMID28092474-Compound-32h | Drug Info | [3] | |||
14 | PMID28092474-Compound-32i | Drug Info | [3] | |||
15 | PMID28092474-Compound-32j | Drug Info | [3] | |||
16 | PMID28092474-Compound-32k | Drug Info | [3] | |||
17 | PMID28092474-Compound-32l | Drug Info | [3] | |||
18 | PMID28092474-Compound-32m | Drug Info | [3] | |||
19 | PMID28092474-Compound-32n | Drug Info | [3] | |||
20 | PMID28092474-Compound-32o | Drug Info | [3] | |||
21 | PMID28092474-Compound-32p | Drug Info | [3] | |||
22 | PMID28092474-Compound-32q | Drug Info | [3] | |||
23 | PMID28092474-Compound-32r | Drug Info | [3] | |||
24 | PMID28092474-Compound-32s | Drug Info | [3] | |||
25 | PMID28092474-Compound-32t | Drug Info | [3] | |||
26 | PMID28092474-Compound-32u | Drug Info | [3] | |||
27 | PMID28092474-Compound-32v | Drug Info | [3] | |||
28 | PMID28092474-Compound-32x | Drug Info | [3] | |||
29 | PMID28092474-Compound-32y | Drug Info | [3] | |||
30 | PMID28092474-Compound-32z | Drug Info | [3] | |||
31 | PMID28092474-Compound-33a | Drug Info | [3] | |||
32 | PMID28092474-Compound-33b | Drug Info | [3] | |||
33 | PMID28092474-Compound-33c | Drug Info | [3] | |||
34 | PMID28092474-Compound-33d | Drug Info | [3] | |||
35 | PMID28092474-Compound-33e | Drug Info | [3] | |||
36 | PMID28092474-Compound-33f | Drug Info | [3] | |||
37 | PMID28092474-Compound-33g | Drug Info | [3] | |||
38 | PMID28092474-Compound-33h | Drug Info | [3] | |||
39 | PMID28092474-Compound-33i | Drug Info | [3] | |||
40 | PMID28092474-Compound-33j | Drug Info | [3] | |||
41 | PMID28092474-Compound-33k | Drug Info | [3] | |||
42 | PMID28092474-Compound-33l | Drug Info | [3] | |||
43 | PMID28092474-Compound-33m | Drug Info | [3] | |||
44 | PMID28092474-Compound-33o | Drug Info | [3] | |||
45 | PMID28092474-Compound-33p | Drug Info | [3] | |||
46 | PMID28092474-Compound-34a | Drug Info | [3] | |||
47 | PMID28092474-Compound-34b | Drug Info | [3] | |||
48 | PMID28092474-Compound-34c | Drug Info | [3] | |||
49 | PMID29671355-Compound-11 | Drug Info | [4] | |||
50 | PMID29671355-Compound-13 | Drug Info | [4] | |||
51 | PMID29671355-Compound-14 | Drug Info | [4] | |||
52 | PMID29671355-Compound-15 | Drug Info | [4] | |||
53 | PMID29671355-Compound-16 | Drug Info | [4] | |||
54 | PMID29671355-Compound-18 | Drug Info | [4] | |||
55 | PMID29671355-Compound-19 | Drug Info | [4] | |||
56 | PMID29671355-Compound-21 | Drug Info | [4] | |||
57 | PMID29671355-Compound-22 | Drug Info | [4] | |||
58 | PMID29671355-Compound-23 | Drug Info | [4] | |||
59 | PMID29671355-Compound-24 | Drug Info | [4] | |||
60 | PMID29671355-Compound-25 | Drug Info | [4] | |||
61 | PMID29671355-Compound-26 | Drug Info | [4] | |||
62 | PMID29671355-Compound-27 | Drug Info | [4] | |||
63 | PMID29671355-Compound-28 | Drug Info | [4] | |||
64 | PMID29671355-Compound-31 | Drug Info | [4] | |||
65 | PMID29671355-Compound-38a | Drug Info | [4] | |||
66 | PMID29671355-Compound-38b | Drug Info | [4] | |||
67 | PMID29671355-Compound-39 | Drug Info | [4] | |||
68 | PMID29671355-Compound-43 | Drug Info | [4] | |||
69 | PMID29671355-Compound-44 | Drug Info | [4] | |||
70 | PMID29671355-Compound-56 | Drug Info | [4] | |||
71 | PMID29671355-Compound-61 | Drug Info | [4] | |||
72 | PMID29671355-Compound-62 | Drug Info | [4] | |||
73 | PMID29671355-Compound-65a | Drug Info | [4] | |||
74 | PMID29671355-Compound-67 | Drug Info | [4] | |||
75 | PMID29671355-Compound-73 | Drug Info | [4] | |||
76 | PMID29671355-Compound-74 | Drug Info | [4] | |||
77 | PMID29671355-Compound-8 | Drug Info | [4] | |||
78 | PMID29671355-Compound-9 | Drug Info | [4] | |||
79 | Sulfonamide derivative 16 | Drug Info | [5] | |||
80 | (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one | Drug Info | [6] | |||
81 | (S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide | Drug Info | [7] | |||
82 | 2-(methylsulfonylthio)ethyl 2-propylpentanoate | Drug Info | [8] | |||
83 | 4-Benzoylamino-N-hydroxy-benzamide | Drug Info | [9] | |||
84 | 4-Butyrylamino-N-hydroxy-benzamide | Drug Info | [10] | |||
85 | 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide | Drug Info | [11] | |||
86 | 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide | Drug Info | [12] | |||
87 | 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide | Drug Info | [13] | |||
88 | 4-Phenylbutyrohydroxamic acid | Drug Info | [14] | |||
89 | 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide | Drug Info | [15] | |||
90 | 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione | Drug Info | [8] | |||
91 | 5-Mercapto-pentanoic acid phenylamide | Drug Info | [12] | |||
92 | 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide | Drug Info | [12] | |||
93 | 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide | Drug Info | [16] | |||
94 | 6-benzenesulfinylhexanoic acid hydroxamide | Drug Info | [17] | |||
95 | 6-benzenesulfonylhexanoic acid hydroxamide | Drug Info | [17] | |||
96 | 6-Mercapto-hexanoic acid phenylamide | Drug Info | [12] | |||
97 | 6-Phenoxy-hexane-1-thiol | Drug Info | [12] | |||
98 | 6-phenylsulfanylhexanoic acid hydroxamide | Drug Info | [17] | |||
99 | 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | [6] | |||
100 | 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one | Drug Info | [11] | |||
101 | 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | [6] | |||
102 | 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | [6] | |||
103 | 7-Mercapto-heptanoic acid benzothiazol-2-ylamide | Drug Info | [12] | |||
104 | 7-Mercapto-heptanoic acid biphenyl-3-ylamide | Drug Info | [12] | |||
105 | 7-Mercapto-heptanoic acid biphenyl-4-ylamide | Drug Info | [12] | |||
106 | 7-Mercapto-heptanoic acid phenylamide | Drug Info | [12] | |||
107 | 7-Mercapto-heptanoic acid pyridin-3-ylamide | Drug Info | [12] | |||
108 | 7-Mercapto-heptanoic acid quinolin-3-ylamide | Drug Info | [12] | |||
109 | 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide | Drug Info | [7] | |||
110 | 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one | Drug Info | [6] | |||
111 | 8-Mercapto-octanoic acid phenylamide | Drug Info | [12] | |||
112 | 8-Oxo-8-phenyl-octanoic acid | Drug Info | [13] | |||
113 | 8-Oxo-8-phenyl-octanoic acid hydroxyamide | Drug Info | [11] | |||
114 | 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide | Drug Info | [11] | |||
115 | 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one | Drug Info | [11] | |||
116 | Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) | Drug Info | [18] | |||
117 | Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) | Drug Info | [18] | |||
118 | Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) | Drug Info | [18] | |||
119 | Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) | Drug Info | [18] | |||
120 | Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) | Drug Info | [18] | |||
121 | Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) | Drug Info | [18] | |||
122 | Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) | Drug Info | [18] | |||
123 | Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) | Drug Info | [18] | |||
124 | Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) | Drug Info | [18] | |||
125 | Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) | Drug Info | [18] | |||
126 | Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) | Drug Info | [18] | |||
127 | Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) | Drug Info | [18] | |||
128 | Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) | Drug Info | [18] | |||
129 | Cyclostellettamine derivative | Drug Info | [19] | |||
130 | droxinostat | Drug Info | [20] | |||
131 | IKH-25 | Drug Info | [21] | |||
132 | N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide | Drug Info | [22] | |||
133 | N-(2-Mercapto-ethyl)-N'-phenyl-succinamide | Drug Info | [22] | |||
134 | N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide | Drug Info | [11] | |||
135 | N-(6-Hydroxycarbamoyl-hexyl)-benzamide | Drug Info | [13] | |||
136 | N-(6-Mercapto-hexyl)-benzamide | Drug Info | [12] | |||
137 | N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide | Drug Info | [23] | |||
138 | N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide | Drug Info | [23] | |||
139 | N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide | Drug Info | [23] | |||
140 | N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide | Drug Info | [23] | |||
141 | N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide | Drug Info | [9] | |||
142 | N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide | Drug Info | [9] | |||
143 | N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide | Drug Info | [9] | |||
144 | N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide | Drug Info | [9] | |||
145 | N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide | Drug Info | [9] | |||
146 | N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide | Drug Info | [9] | |||
147 | N-Hydroxy-4-(pentanoylamino-methyl)-benzamide | Drug Info | [10] | |||
148 | N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide | Drug Info | [10] | |||
149 | N-Hydroxy-4-phenylacetylamino-benzamide | Drug Info | [9] | |||
150 | N-phenyl-6-(sulfamoylamino)hexanamide | Drug Info | [23] | |||
151 | N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide | Drug Info | [24] | |||
152 | N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide | Drug Info | [23] | |||
153 | N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide | Drug Info | [25] | |||
154 | N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide | Drug Info | [25] | |||
155 | nexturastat A | Drug Info | [26] | |||
156 | NILTUBACIN | Drug Info | [14] | |||
157 | NQN-1 | Drug Info | [27] | |||
158 | Octanedioic acid bis-hydroxyamide | Drug Info | [28] | |||
159 | Octanedioic acid hydroxyamide pyridin-2-ylamide | Drug Info | [13] | |||
160 | Octanedioic acid hydroxyamide pyridin-4-ylamide | Drug Info | [13] | |||
161 | PMID19111466C7d | Drug Info | [29] | |||
162 | PMID20947351C16 | Drug Info | [16] | |||
163 | PSAMMAPLIN A | Drug Info | [11] | |||
164 | santacruzamate A | Drug Info | [30] | |||
165 | ST-2741 | Drug Info | [31] | |||
166 | ST-2986 | Drug Info | [32] | |||
167 | ST-2987 | Drug Info | [32] | |||
168 | ST-3050 | Drug Info | [32] | |||
169 | Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester | Drug Info | [12] | |||
170 | Tubacin | Drug Info | [33], [34] | |||
171 | UCL-67022 | Drug Info | [21] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: N-(4-Methylthiazol-2-yl)acetamide | Ligand Info | |||||
Structure Description | Crystal structure of a low occupancy fragment candidate (N-(4-Methyl-1,3-thiazol-2-yl)propanamide) bound adjacent to the ubiquitin binding pocket of the HDAC6 zinc-finger domain | PDB:5B8D | ||||
Method | X-ray diffraction | Resolution | 1.05 Å | Mutation | No | [35] |
PDB Sequence |
PLPWCPHLVA
1118 VCPIPAAGLD1128 VTQPCGDCGT1138 IQENWVCLSC1148 YQVYCGRYIN1158 GHMLQHHGNS 1168 GHPLVLSYID1178 LSAWCYYCQA1188 YVHHQALLDV1198 KNIAHQNKFG1208 |
|||||
|
||||||
Ligand Name: 6-Methyl-5-[(4-Propan-2-Ylphenyl)amino]-2~{h}-1,2,4-Triazin-3-One | Ligand Info | |||||
Structure Description | Crystal structure of a low occupancy fragment candidate (5-[(4-Isopropylphenyl)amino]-6-methyl-1,2,4-triazin-3(2H)-one) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain | PDB:5KH9 | ||||
Method | X-ray diffraction | Resolution | 1.07 Å | Mutation | No | [35] |
PDB Sequence |
PLPWCPHLVA
1118 VCPIPAAGLD1128 VTQPCGDCGT1138 IQENWVCLSC1148 YQVYCGRYIN1158 GHMLQHHGNS 1168 GHPLVLSYID1178 LSAWCYYCQA1188 YVHHQALLDV1198 KNIAHQNKFG1208 |
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Neutrophil extracellular trap formation | hsa04613 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy |
Degree | 20 | Degree centrality | 2.15E-03 | Betweenness centrality | 3.83E-03 |
---|---|---|---|---|---|
Closeness centrality | 2.54E-01 | Radiality | 1.44E+01 | Clustering coefficient | 8.95E-02 |
Neighborhood connectivity | 5.04E+01 | Topological coefficient | 6.77E-02 | Eccentricity | 11 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) | ||||||
Drug Resistance Mutation (DRM) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
1 | Alcoholism | |||||
2 | Viral carcinogenesis | |||||
PID Pathway | [+] 2 PID Pathways | + | ||||
1 | Signaling events mediated by HDAC Class II | |||||
2 | Signaling events mediated by HDAC Class I | |||||
Reactome | [+] 4 Reactome Pathways | + | ||||
1 | NOTCH1 Intracellular Domain Regulates Transcription | |||||
2 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
3 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
4 | Assembly of the primary cilium | |||||
WikiPathways | [+] 3 WikiPathways | + | ||||
1 | Ectoderm Differentiation | |||||
2 | Neural Crest Differentiation | |||||
3 | Cell Cycle |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Promising therapies in multiple myeloma. Blood. 2015 July 16; 126(3): 300-310. | |||||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 3 | Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. | |||||
REF 4 | HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. | |||||
REF 5 | Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549. | |||||
REF 6 | Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. | |||||
REF 7 | Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38. | |||||
REF 8 | New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. | |||||
REF 9 | Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. | |||||
REF 10 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. | |||||
REF 11 | Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. | |||||
REF 12 | Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. | |||||
REF 13 | Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. | |||||
REF 14 | Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. | |||||
REF 15 | Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. | |||||
REF 16 | Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70. | |||||
REF 17 | Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. | |||||
REF 18 | Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. | |||||
REF 19 | Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. | |||||
REF 20 | Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56. | |||||
REF 21 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618). | |||||
REF 22 | Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. | |||||
REF 23 | Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. | |||||
REF 24 | Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett. 2004 Jan 19;14(2):449-53. | |||||
REF 25 | Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. | |||||
REF 26 | Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9. | |||||
REF 27 | A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol. 2012 Feb 17;7(2):331-9. | |||||
REF 28 | Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309. | |||||
REF 29 | Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):688-92. | |||||
REF 30 | Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. | |||||
REF 31 | Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3. | |||||
REF 32 | N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. | |||||
REF 33 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||||
REF 34 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||||
REF 35 | Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin. J Med Chem. 2017 Nov 9;60(21):9090-9096. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.